Media stories about Haemonetics Corporation (NYSE:HAE) have trended somewhat positive this week, Accern reports. The research group identifies negative and positive press coverage by monitoring more than twenty million blog and news sources in real-time. Accern ranks coverage of publicly-traded companies on a scale of -1 to 1, with scores closest to one being the most favorable. Haemonetics Corporation earned a media sentiment score of 0.11 on Accern’s scale. Accern also gave headlines about the medical instruments supplier an impact score of 46.4284138715791 out of 100, indicating that recent press coverage is somewhat unlikely to have an effect on the stock’s share price in the near term.

Several equities research analysts have recently commented on HAE shares. BidaskClub lowered Haemonetics Corporation from a “hold” rating to a “sell” rating in a research note on Friday, June 23rd. Barrington Research raised Haemonetics Corporation from a “market perform” rating to an “outperform” rating and set a $48.00 price target on the stock in a research note on Tuesday, August 8th. Zacks Investment Research raised Haemonetics Corporation from a “hold” rating to a “buy” rating and set a $46.00 target price on the stock in a research note on Thursday, August 24th. TheStreet raised Haemonetics Corporation from a “c” rating to a “b-” rating in a research note on Monday, August 7th. Finally, Jefferies Group LLC reaffirmed a “buy” rating and issued a $48.00 target price on shares of Haemonetics Corporation in a research note on Thursday, July 27th. Two analysts have rated the stock with a sell rating, three have given a hold rating and three have issued a buy rating to the company’s stock. The stock presently has an average rating of “Hold” and a consensus price target of $41.67.

Shares of Haemonetics Corporation (NYSE HAE) opened at 45.75 on Thursday. The company has a 50-day moving average price of $42.78 and a 200-day moving average price of $41.29. The stock has a market cap of $2.41 billion, a price-to-earnings ratio of 594.16 and a beta of 0.87. Haemonetics Corporation has a 1-year low of $32.76 and a 1-year high of $46.85.

Haemonetics Corporation (NYSE:HAE) last posted its quarterly earnings data on Monday, August 7th. The medical instruments supplier reported $0.33 EPS for the quarter, topping analysts’ consensus estimates of $0.31 by $0.02. Haemonetics Corporation had a net margin of 0.48% and a return on equity of 11.07%. The firm had revenue of $211.00 million during the quarter, compared to analyst estimates of $211.29 million. During the same quarter last year, the business posted $0.25 EPS. The company’s revenue was up .5% on a year-over-year basis. On average, equities analysts expect that Haemonetics Corporation will post $1.60 earnings per share for the current fiscal year.

COPYRIGHT VIOLATION NOTICE: “Somewhat Positive Media Coverage Somewhat Unlikely to Impact Haemonetics Corporation (HAE) Share Price” was first posted by Watch List News and is the property of of Watch List News. If you are accessing this piece of content on another site, it was stolen and republished in violation of international copyright and trademark law. The legal version of this piece of content can be accessed at https://www.watchlistnews.com/somewhat-positive-media-coverage-somewhat-unlikely-to-impact-haemonetics-corporation-hae-share-price/1610131.html.

Haemonetics Corporation Company Profile

Haemonetics Corporation (Haemonetics) is a healthcare company. The Company provides various products to customers involved in the processing, handling and analysis of blood. The Company’s segments include Japan, EMEA, North America Plasma and All Other. Haemonetics provides plasma collection systems and software, which enable plasma fractionators to make pharmaceuticals.

Insider Buying and Selling by Quarter for Haemonetics Corporation (NYSE:HAE)

Receive News & Ratings for Haemonetics Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Haemonetics Corporation and related companies with Analyst Ratings Network's FREE daily email newsletter.